AR072245A1 - Proceso para minimizar el polimorfismo, forma de dosaje de dispersion rapida solida oral - Google Patents

Proceso para minimizar el polimorfismo, forma de dosaje de dispersion rapida solida oral

Info

Publication number
AR072245A1
AR072245A1 ARP090100677A ARP090100677A AR072245A1 AR 072245 A1 AR072245 A1 AR 072245A1 AR P090100677 A ARP090100677 A AR P090100677A AR P090100677 A ARP090100677 A AR P090100677A AR 072245 A1 AR072245 A1 AR 072245A1
Authority
AR
Argentina
Prior art keywords
suspension
process according
dosage form
carrier material
pharmaceutically active
Prior art date
Application number
ARP090100677A
Other languages
English (en)
Inventor
Rosie Mclaughlin
Andrew Jordan
Simon Howes
Wei Tian
Original Assignee
Rp Scherer Technologies Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rp Scherer Technologies Llc filed Critical Rp Scherer Technologies Llc
Publication of AR072245A1 publication Critical patent/AR072245A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicacion 1: Un proceso para preparar una forma de dosaje de dispersion rápida solida oral de una sustancia activa farmacéuticamente en la cual dicha sustancia presenta polimorfismo en un ambiente acuoso, que comprende los siguientes pasos; (a) formacion de una suspension de partículas de dicha sustancia en un material vehículo en una fase continua, en donde el material vehículo es gelatina de pescado de peso molecular estándar; (b) reduccion de la temperatura de la suspension a menos de alrededor de 15°C; (c) formacion de unidades discretas de la suspension a una temperatura de formacion de menos de alrededor 15°C; y (d) eliminacion de la fase continua para dejar la suspension de las partículas en el material vehículo. Reivindicacion 2: El proceso segun la reivindicacion 1, en donde la fase continua es agua. Reivindicacion 4: El proceso segun la reivindicacion 3, en donde la sustancia activa farmacéuticamente es una droga benzodiazepina. Reivindicacion 5: El proceso segun la reivindicacion 1, en donde la sustancia activa farmacéuticamente es alprazolam. Reivindicacion 7: El proceso segun la reivindicacion 1, en donde dicha suspension comprende además al menos un ingrediente adicional seleccionado del grupo consistente en agentes colorantes, agentes saborizantes, excipientes, otros agentes terapéuticos y sus combinaciones.
ARP090100677A 2008-02-28 2009-02-27 Proceso para minimizar el polimorfismo, forma de dosaje de dispersion rapida solida oral AR072245A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3229808P 2008-02-28 2008-02-28

Publications (1)

Publication Number Publication Date
AR072245A1 true AR072245A1 (es) 2010-08-18

Family

ID=41016708

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090100677A AR072245A1 (es) 2008-02-28 2009-02-27 Proceso para minimizar el polimorfismo, forma de dosaje de dispersion rapida solida oral

Country Status (19)

Country Link
US (1) US20090226522A1 (es)
EP (1) EP2247284B1 (es)
JP (2) JP5547096B2 (es)
KR (1) KR101473419B1 (es)
CN (2) CN103751091B (es)
AR (1) AR072245A1 (es)
AU (1) AU2009219292B2 (es)
BR (1) BRPI0908539B8 (es)
CA (1) CA2716901C (es)
DK (1) DK2247284T3 (es)
ES (1) ES2633928T3 (es)
HK (1) HK1154505A1 (es)
IL (2) IL207824A (es)
MX (1) MX2010009493A (es)
MY (1) MY173867A (es)
NZ (1) NZ587611A (es)
RU (1) RU2010139643A (es)
WO (1) WO2009108775A2 (es)
ZA (1) ZA201006421B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6061859B2 (ja) * 2010-10-08 2017-01-18 アール．ピー． シェーラー テクノロジーズ エルエルシー デンプンを使用する経口ワクチン速溶性剤型
AU2016222550B2 (en) 2015-02-27 2020-07-16 Dechra Limited Stimulation of appetite, management of weight loss, and treatment of anorexia in dogs and cats
CN107951893B (zh) * 2016-10-18 2022-04-26 天津金耀集团有限公司 一种糠酸莫米松粉吸入剂组合物
EP4368169A2 (en) 2016-12-31 2024-05-15 Bioxcel Therapeutics, Inc. Use of sublingual dexmedetomidine for the treatment of agitation
SG11202012772XA (en) 2018-06-27 2021-01-28 Bioxcel Therapeutics Inc Film formulations containing dexmedetomidine and methods of producing them
CN109010295A (zh) * 2018-08-29 2018-12-18 北京兴源联合医药科技有限公司 一种左甲状腺素钠冻干口腔崩解片
CN109316452B (zh) * 2018-09-07 2021-07-30 北京兴源联合医药科技有限公司 一种硫酸氢氯吡格雷冻干口腔崩解片
CA3129434A1 (en) 2019-02-22 2020-08-27 Catalent U.K. Swindon Zydis Limited Minimizing agglomeration of drug particle coating material during storage to stabilize disintegration times of pharmaceutical products
KR20210129649A (ko) 2019-02-22 2021-10-28 카탈렌트 유.케이. 스윈던 지디스 리미티드 이부프로펜을 포함하는 약학적 조성물의 응집, 에어레이션 최소화 및 코팅 보존
KR20220049526A (ko) 2019-07-19 2022-04-21 바이오엑셀 테라퓨틱스 인코포레이티드 비-진정성 덱스메데토미딘 치료 양생법
CA3189404A1 (en) * 2020-07-31 2022-02-03 Catalent U.K. Swindon Zydis Limited Pharmaceutical compositions comprising coated api
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1548022A (en) * 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
US4946684A (en) * 1989-06-20 1990-08-07 American Home Products Corporation Fast dissolving dosage forms
DD289468B5 (de) 1989-11-07 1994-02-10 Dresden Arzneimittel Arzneimitteltechnologisches verfahren zur herstellung einer alprazolam-arzneiform
CA2020018A1 (en) * 1990-06-27 1991-12-28 Don L. Simmons Method and composition for treating the migraine complex
ATE216577T1 (de) * 1992-01-29 2002-05-15 Takeda Chemical Industries Ltd Schnellösliche tablette und ihre herstellung
AU691195B2 (en) * 1993-07-09 1998-05-14 R.P. Scherer Corporation Method for making freeze dried drug dosage forms
US5457895A (en) * 1993-10-01 1995-10-17 R. P. Scherer Corporation Method of identifying freeze-dried dosage forms
CZ289649B6 (cs) 1994-07-22 2002-03-13 Krka, Tovarna Zdravil. P.O. Pevné lékové formy se spolehlivým uvolňováním aktivní sloľky alprazolamu a způsob jejich přípravy
EP0893992B1 (en) * 1996-04-16 2004-03-03 Novartis Consumer Health S.A. Fast disintegrating oral dosage form
US5958453A (en) * 1996-10-31 1999-09-28 Takeda Chemical Industries, Ltd. Solid pharmaceutical preparation with improved buccal disintegrability and/or dissolubility
US5869098A (en) * 1997-08-20 1999-02-09 Fuisz Technologies Ltd. Fast-dissolving comestible units formed under high-speed/high-pressure conditions
US6010719A (en) * 1997-09-16 2000-01-04 Universiteit Gent Freeze-dried disintegrating tablets
DK1042405T3 (da) 1997-12-26 2005-04-18 Warner Lambert Co Gelatinesammensætninger
GB9908014D0 (en) * 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
US6509040B1 (en) * 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
ES2284871T3 (es) * 2001-06-22 2007-11-16 Pfizer Products Inc. Composiciones farmaceuticas que contienen una dispersion solida de farmaco poco soluble y un polimero potenciador de la solubilidad.
US7972621B2 (en) * 2004-06-03 2011-07-05 R.P. Scherer Technologies, Llc Process for formulating fast dispersing dosage forms comprising at least one fish gelatin selected on the basis of molecular weight
US7855196B2 (en) * 2005-08-22 2010-12-21 Pierre Mainville Composition comprising a benzodiazepine agonist and a benzodiazepine antagonist
CN101304750A (zh) * 2005-11-09 2008-11-12 陶氏制药科学公司 用于治疗肉芽肿性酒糟鼻的阿奇霉素
GB0714223D0 (en) * 2007-07-20 2007-08-29 Fujifilm Mfg Europe Bv Preparation of fine particles

Also Published As

Publication number Publication date
US20090226522A1 (en) 2009-09-10
EP2247284B1 (en) 2017-04-19
WO2009108775A2 (en) 2009-09-03
CN102036655B (zh) 2013-11-20
MY173867A (en) 2020-02-25
AU2009219292A1 (en) 2009-09-03
MX2010009493A (es) 2010-12-20
IL207824A (en) 2017-11-30
BRPI0908539B8 (pt) 2021-05-25
IL207824A0 (en) 2010-12-30
WO2009108775A3 (en) 2009-12-03
CN102036655A (zh) 2011-04-27
RU2010139643A (ru) 2012-04-10
IL252713A0 (en) 2017-08-31
EP2247284A4 (en) 2013-10-02
KR20100123740A (ko) 2010-11-24
ZA201006421B (en) 2011-05-25
ES2633928T3 (es) 2017-09-26
JP2014062119A (ja) 2014-04-10
JP5547096B2 (ja) 2014-07-09
CA2716901C (en) 2018-07-03
CN103751091B (zh) 2017-08-25
CN103751091A (zh) 2014-04-30
KR101473419B1 (ko) 2014-12-16
JP2011513324A (ja) 2011-04-28
EP2247284A2 (en) 2010-11-10
AU2009219292B2 (en) 2014-02-27
CA2716901A1 (en) 2009-09-03
NZ587611A (en) 2012-07-27
BRPI0908539B1 (pt) 2020-12-08
DK2247284T3 (en) 2017-07-31
HK1154505A1 (en) 2012-04-27

Similar Documents

Publication Publication Date Title
AR072245A1 (es) Proceso para minimizar el polimorfismo, forma de dosaje de dispersion rapida solida oral
HRP20180007T1 (hr) Formulacija koja sadrži gemcitabin-predlijek
CY1120230T1 (el) Προϊον χορηγησης απο του στοματος
JP5073651B2 (ja) 抗ウィルス剤、抗腫瘍剤または抗寄生虫剤ならびにカルベオール、チモール、オイゲノール、ボルネオールおよびカルバクロールから選択される活性剤を含んでなる製薬組成物
HRP20160605T1 (hr) Tetraciklički spoj
JP2016517888A5 (es)
PH12015502134B1 (en) Mosapride sustained-release formulation providing pharmacological and clinical effects with once-daily administration
MA37206B1 (fr) Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ES2705529T3 (es) Tratamiento combinatorio del cáncer
Kumar et al. Optimization of combinational intranasal drug delivery system for the management of migraine by using statistical design
GT200800145A (es) Una composicion solida de taxano liofilizada, un procedimiento para preparar dicha composicion solida, una formulacion farmaceutica y un conjunto (kit) de dicha formulacion
EA201590449A1 (ru) Перорально вводимая лекарственная композиция
CN103547260A (zh) 用于治疗中枢系统疾病的包含Brexpiprazole或其盐和第二种药物的组合
BRPI0716436B8 (pt) sistema de liberação controlada e método para fabricação do mesmo
KR20240006536A (ko) 항바이러스제로서의 티오뉴클레오시드
JP2010518086A5 (es)
CO5060477A1 (es) Forma de dosificacion de nefazodona
AR084865A1 (es) Preparacion de desintegracion rapida, comprimido dispersable por via oral
MY160652A (en) Pharmaceutical composition for oral administration
DOP2009000255A (es) Extrudidos con enmascaramiento del sabor mejorado
JP2013523676A5 (es)
RU2012141141A (ru) Быстрорастворимая фармацевтическая композиция
CO6170417A2 (es) Formulaciones orales liofilizadas de desintegracion rapida de un antagonista del receptor de trombina
RU2015134148A (ru) Галеновая форма для введения активного действующего вещества
PE20130782A1 (es) Composiciones farmaceuticas que consisten de paracetamol y el proceso para la preparacion del mismo

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
FC Refusal